Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer

Todd M. Pitts, Erica L. Bradshaw-Pierce, Stacey M. Bagby, Stephanie L. Hyatt, Heather M. Selby, Anna Spreafico, John J. Tentler, Kelly McPhillips, Peter J. Klauck, Anna Capasso, Jennifer R. Diamond, S. Lindsey Davis, Aik-Choon Tan, John J. Arcaroli, Alicia Purkey, Wells A. Messersmith, Jeffery A. Ecsedy, S. Gail Eckhardt

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC. Results: CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to alisertib we observed a decrease in pAurora A, B and C in four CRC cell lines. We also observed an increase in p53 and p21 in a sensitive p53 wildtype cell line in contrast to the p53 mutant cell line or the resistant cell lines. The addition of alisertib to standard CRC treatments demonstrated improvement over single agent arms; however, the benefit was largely less than additive, but not antagonistic. Methods: Forty-seven CRC cell lines were exposed to alisertib and IC50s were calculated. Twenty-one PDX models were treated with alisertib and the Tumor Growth Inhibition Index was assessed. Additionally, 5 KRAS wildtype and mutant PDX models were treated with alisertib as single agent or in combination with cetuximab or irinotecan, respectively. Conclusion: Alisertib demonstrated anti-proliferative effects against CRC cell lines and PDX models. Our data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.

Original languageEnglish
Pages (from-to)50290-50301
Number of pages12
JournalOncotarget
Volume7
Issue number31
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Phosphotransferases
Cell Line
irinotecan
Aurora Kinases
MLN 8237
Protein-Serine-Threonine Kinases
Patient Selection
Inhibitory Concentration 50
Neoplasms
Growth

Keywords

  • Aurora kinase a
  • Colorectal cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Pitts, T. M., Bradshaw-Pierce, E. L., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., ... Eckhardt, S. G. (2016). Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget, 7(31), 50290-50301. https://doi.org/10.18632/oncotarget.10366

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. / Pitts, Todd M.; Bradshaw-Pierce, Erica L.; Bagby, Stacey M.; Hyatt, Stephanie L.; Selby, Heather M.; Spreafico, Anna; Tentler, John J.; McPhillips, Kelly; Klauck, Peter J.; Capasso, Anna; Diamond, Jennifer R.; Lindsey Davis, S.; Tan, Aik-Choon; Arcaroli, John J.; Purkey, Alicia; Messersmith, Wells A.; Ecsedy, Jeffery A.; Eckhardt, S. Gail.

In: Oncotarget, Vol. 7, No. 31, 2016, p. 50290-50301.

Research output: Contribution to journalArticle

Pitts, TM, Bradshaw-Pierce, EL, Bagby, SM, Hyatt, SL, Selby, HM, Spreafico, A, Tentler, JJ, McPhillips, K, Klauck, PJ, Capasso, A, Diamond, JR, Lindsey Davis, S, Tan, A-C, Arcaroli, JJ, Purkey, A, Messersmith, WA, Ecsedy, JA & Eckhardt, SG 2016, 'Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer', Oncotarget, vol. 7, no. 31, pp. 50290-50301. https://doi.org/10.18632/oncotarget.10366
Pitts, Todd M. ; Bradshaw-Pierce, Erica L. ; Bagby, Stacey M. ; Hyatt, Stephanie L. ; Selby, Heather M. ; Spreafico, Anna ; Tentler, John J. ; McPhillips, Kelly ; Klauck, Peter J. ; Capasso, Anna ; Diamond, Jennifer R. ; Lindsey Davis, S. ; Tan, Aik-Choon ; Arcaroli, John J. ; Purkey, Alicia ; Messersmith, Wells A. ; Ecsedy, Jeffery A. ; Eckhardt, S. Gail. / Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. In: Oncotarget. 2016 ; Vol. 7, No. 31. pp. 50290-50301.
@article{cea366e9cbd74aa2acc0b468a8c32fa8,
title = "Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer",
abstract = "Background: The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC. Results: CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to alisertib we observed a decrease in pAurora A, B and C in four CRC cell lines. We also observed an increase in p53 and p21 in a sensitive p53 wildtype cell line in contrast to the p53 mutant cell line or the resistant cell lines. The addition of alisertib to standard CRC treatments demonstrated improvement over single agent arms; however, the benefit was largely less than additive, but not antagonistic. Methods: Forty-seven CRC cell lines were exposed to alisertib and IC50s were calculated. Twenty-one PDX models were treated with alisertib and the Tumor Growth Inhibition Index was assessed. Additionally, 5 KRAS wildtype and mutant PDX models were treated with alisertib as single agent or in combination with cetuximab or irinotecan, respectively. Conclusion: Alisertib demonstrated anti-proliferative effects against CRC cell lines and PDX models. Our data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.",
keywords = "Aurora kinase a, Colorectal cancer",
author = "Pitts, {Todd M.} and Bradshaw-Pierce, {Erica L.} and Bagby, {Stacey M.} and Hyatt, {Stephanie L.} and Selby, {Heather M.} and Anna Spreafico and Tentler, {John J.} and Kelly McPhillips and Klauck, {Peter J.} and Anna Capasso and Diamond, {Jennifer R.} and {Lindsey Davis}, S. and Aik-Choon Tan and Arcaroli, {John J.} and Alicia Purkey and Messersmith, {Wells A.} and Ecsedy, {Jeffery A.} and Eckhardt, {S. Gail}",
year = "2016",
doi = "10.18632/oncotarget.10366",
language = "English",
volume = "7",
pages = "50290--50301",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer

AU - Pitts, Todd M.

AU - Bradshaw-Pierce, Erica L.

AU - Bagby, Stacey M.

AU - Hyatt, Stephanie L.

AU - Selby, Heather M.

AU - Spreafico, Anna

AU - Tentler, John J.

AU - McPhillips, Kelly

AU - Klauck, Peter J.

AU - Capasso, Anna

AU - Diamond, Jennifer R.

AU - Lindsey Davis, S.

AU - Tan, Aik-Choon

AU - Arcaroli, John J.

AU - Purkey, Alicia

AU - Messersmith, Wells A.

AU - Ecsedy, Jeffery A.

AU - Eckhardt, S. Gail

PY - 2016

Y1 - 2016

N2 - Background: The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC. Results: CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to alisertib we observed a decrease in pAurora A, B and C in four CRC cell lines. We also observed an increase in p53 and p21 in a sensitive p53 wildtype cell line in contrast to the p53 mutant cell line or the resistant cell lines. The addition of alisertib to standard CRC treatments demonstrated improvement over single agent arms; however, the benefit was largely less than additive, but not antagonistic. Methods: Forty-seven CRC cell lines were exposed to alisertib and IC50s were calculated. Twenty-one PDX models were treated with alisertib and the Tumor Growth Inhibition Index was assessed. Additionally, 5 KRAS wildtype and mutant PDX models were treated with alisertib as single agent or in combination with cetuximab or irinotecan, respectively. Conclusion: Alisertib demonstrated anti-proliferative effects against CRC cell lines and PDX models. Our data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.

AB - Background: The Aurora kinases are a family of serine/threonine kinases comprised of Aurora A, B, and C which execute critical steps in mitotic and meiotic progression. Alisertib (MLN8237) is an investigational Aurora A selective inhibitor that has demonstrated activity against a wide variety of tumor types in vitro and in vivo, including CRC. Results: CRC cell lines demonstrated varying sensitivity to alisertib with IC50 values ranging from 0.06 to > 5 umol/L. Following exposure to alisertib we observed a decrease in pAurora A, B and C in four CRC cell lines. We also observed an increase in p53 and p21 in a sensitive p53 wildtype cell line in contrast to the p53 mutant cell line or the resistant cell lines. The addition of alisertib to standard CRC treatments demonstrated improvement over single agent arms; however, the benefit was largely less than additive, but not antagonistic. Methods: Forty-seven CRC cell lines were exposed to alisertib and IC50s were calculated. Twenty-one PDX models were treated with alisertib and the Tumor Growth Inhibition Index was assessed. Additionally, 5 KRAS wildtype and mutant PDX models were treated with alisertib as single agent or in combination with cetuximab or irinotecan, respectively. Conclusion: Alisertib demonstrated anti-proliferative effects against CRC cell lines and PDX models. Our data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.

KW - Aurora kinase a

KW - Colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84981297926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981297926&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10366

DO - 10.18632/oncotarget.10366

M3 - Article

C2 - 27385211

AN - SCOPUS:84981297926

VL - 7

SP - 50290

EP - 50301

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -